ACF Bioservices

Home>>Tag: ACF Bioservices

Using Empty AAV Capsids to Reduce Inhibitory Effect of Neutralizing Antibodies on AAV Transduction

Using Empty AAV Capsids to Reduce Inhibitory Effect of Neutralizing Antibodies on AAV Transduction Jiu Jiang, PhD1, Steven Wright, PhD2, and Ismael Hidalgo, PhD1 1Absorption Systems LLC, 436 [...]

2019-11-13T09:54:15-05:00November 13, 2019|Categories: ACF Bioservices|Tags: , , |

Gene Therapy in Combination: A Promising Avenue for Cancer Treatment

Gene therapies (GTs) are a rapidly growing field of cancer treatment, with almost 2000 active clinical trials worldwide representing 65% of total gene therapies. There is particular [...]

2019-10-04T15:39:34-05:00October 4, 2019|Categories: AbsorbThis Blog, ACF Bioservices|Tags: , |

Why Cell & Gene Therapy Focuses on the Eye

Many companies are developing cell and gene therapy for ocular diseases. There are more than 25 companies developing cell and gene therapy (CGT) for ocular diseases with more [...]

Key Takeaways from The Bioprocessing Summit: Gene Therapy CMC and Analytics

Last week, at The Bioprocessing Summit in Boston’s Seaport district, we heard from industry leaders on their CMC and analytical strategies for developing gene therapy products. This was [...]

Presentation: In Vitro Relative Potency Assays for Commercialization of Gene Therapy Products

Presentation: In Vitro Relative Potency Assays for Commercialization of Gene Therapy Products Originally Presented: Monday, April 29, 2019 ASGCT Annual Meeting Washington, DC Presenter: Karen Doucette, MBA [...]

2019-05-07T09:56:15-05:00May 6, 2019|Categories: ACF Bioservices|Tags: , , |